Vivos Therapeutics, Inc. (VVOS) To Buy 11% of SOD Sciences, 50% of Pseudohypoxia Test IP via $12M Preferred
Vivos Therapeutics (VVOS) agreed to buy 11% of SOD Sciences and 50% of its pseudohypoxia test IP for $12M in Series C Convertible Preferred Stock. The deal is expected to close by October 15, 2026, pending conditions. VVOS aims to strengthen its equity and revenue streams as part of its Nasdaq compliance efforts.
How this was made
The 30-second read
Why it matters
The acquisition could diversify Vivos' revenue base if the pseudohypoxia test achieves clinical validation, but the $12M valuation suggests modest immediate impact.
Market read
A small‑cap M&A announcement that may provide incremental upside for Vivos but is unlikely to drive significant market movement.
What to watch
Potential regulatory or clinical validation hurdles for the pseudohypoxia test could delay revenue generation.
Background
Vivos Therapeutics is seeking to strengthen its pipeline and meet Nasdaq compliance through strategic, non‑cash deals.
Ticker impact
Vivos Therapeutics announced a definitive agreement to purchase an 11% stake in SOD Sciences and 50% of related IP for $12M of Series C Convertible Preferred Stock.
limited upside as the market prices in the strategic acquisition, but no strong directional pressure.
First‑report of a small‑cap M&A transaction; the amount is modest and the closing is conditional, so price reaction is likely muted.
Market effects
Adds a modest strategic partnership in the biotech/diagnostics space, but unlikely to shift sector dynamics.
Primarily affects US micro‑cap market; no broader regional effect.
Limited to Vivos shareholders and niche investors.
Counterpoint
The small size and conditional closing may mean the deal will not materialize, limiting upside.
Key entities
- CompanyVivos Therapeutics, Inc.
US‑listed biotech firm executing the acquisition.
- CompanySOD Sciences
Target of the 11% equity stake and IP co‑ownership.
